An investigative reporter wrote a very interesting article

New Post Public Reply Private Reply Replies (1) Message Board
Enjay
1,157
An investigative reporter wrote a very interesting article on the FDA and Ivermectin. I am posting this so you can see what the reporter turned up about the FDA, not Ivermectin. The article was published on rescue.substack.com and I will post a link to the article below. I am not familiar with that website, but the FOIA emails look authentic. The article is rather long, but I hope the excerpts I am posting below entice you to read the entire article at the link.

In a hokey tweet on August 21, the U.S. Food and Drug Administration told Americans the obvious: “You are not a horse. You are not a cow. Seriously, y’all. Stop it.”
Everyone knew what “it” was: an animal form of the drug ivermectin that folks were said to be using, widely, for covid-19. Don’t, said FDA.

Within two days, 23.7 million people had seen that Pulitzer-worthy bit of Twitter talk. Hundreds of thousands more got the message on Facebook, LinkedIn, and from the Today Show’s 3 million-follower Instagram account.

There was one problem, however. The tweet was a direct outgrowth of wrong data—call it misinformation—put out the day before by the Mississippi health department. The FDA did not vet the data, according to our review of emails obtained under the Freedom of Information Act and questions to FDA officials. Instead, it saw Mississippi, as one email said, as “an opportunity to remind the public of our own warnings for ivermectin.”

It began with one sentence in a Mississippi health alert on reports to the state’s poison control center: “At least 70% of the recent calls have been related to ingestion of livestock or animal formulations of ivermectin purchased at livestock supply centers.” In the thick of a fierce covid wave in the American South, no official at the FDA, or reporter for that matter, seemed to ask: 70 percent of what? Instead, government and media joined forces against a public health threat that, in retrospect, was vastly exaggerated.

Amid dozens of articles that ensued, Rolling Stone told of Oklahoma hospitals so jammed with ivermectin overdoses that gunshot victims had to wait for care—except it wasn’t true. Twice, The New York Times printed corrections of the same false information from Mississippi, which it described in one article and later removed, as “a staggering number of calls.” The Associated Press, Washington Post and, twice, the The Guardian in London also corrected its reporting on the alert.

The Times’ correction summed it up: “This article misstated the percentage of recent calls to the Mississippi poison control center related to ivermectin. It was 2 percent, not 70 percent.” (The Times and Post both made corrections in direct response to our reporting for this article.)
In real numbers, six calls were received for ingestion of ivermectin. Four were for the antiparasitic drug given to livestock.

So how big was the surge that FDA described as “multiple”? Four, an agency spokesperson said just after the page went up. Three people were hospitalized, but it wasn’t clear if that was for covid itself. When pressed for details, FDA cited privacy issues, and said in an email, “Some of these cases were lost to follow up.”
This is how government gets away with some whoppers, and with the media’s help.

Below, FDA officials crow over the deception that was “the most popular post we’ve ever had on Twitter:”

1811865471_FDA(Erica)8-23-21email.png

…and the FDA commissioner was thrilled:

1058964438_Woodcockemail.png

In this email obtained by Linda Bonvie under the Freedom of Information Act, FDA officials celebrate reaching the “everyday” American with a tweet that sparked a media firestorm of lies:

346533143_FDA(Erica)8-22-21email.png

Here is the link for the entire article:
https://rescue.substack.com/p/horse-bleep-how...-on-animal

Here is the FDA's bio for Erica Jefferson, Associate Commissioner for External Affairs.
https://www.fda.gov/about-fda/fda-organizatio...-jefferson

Interesting follow-up note: Mary Beth Pfeiffer, the investigative journalist who wrote the article, was locked out of Twitter for violating their rules one day after the article appeared. She was gaining lots of new followers until the lockout.
https://rescue.substack.com/p/a-day-after-our...tm_source=

So many interesting points could be made about this. Here are the first few I thought about:

The FDA has an External Affairs Department ready to move quickly, even on erroneous data.

The FDA tracks number of hits on tweets and new followers.

Now think about their unsigned hit-piece on Leronlimab. I wonder if they also counted the hits on that one and then celebrated?

I know I am "preaching to the choir" about the FDA, but the FOIA emails are (pick one or use your own): amazing - astounding - appalling - disappointing....................................

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 5

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Veriforce Expands Its Mission with Highwire Acquisition

Updated Category News Views 471

Veriforce Expands Its Mission with Highwire Acquisition The combined expertise delivers stronger safety, compliance, and financial risk management for construction projects worldwide Veriforce, a leader in contractor management and supply chain risk management, has recently announced its acquisition of Highwire. This acquisition is significant in the realm of contractor...

Continue Reading
Tyra Biosciences Achieves Key Preclinical Results, Analysts Upgrades

Updated Category News Views 104

Tyra Biosciences Receives Analyst Upgrade BofA Securities has recently upgraded Tyra Biosciences (NASDAQ: TYRA), a clinical-stage biotechnology firm specializing in the creation of next-generation precision medicines. This upgrade highlights investor optimism as the company demonstrates promising results in its drug development process. Focus on Precision Medicine in...

Continue Reading
ConnX Partners with SEPTA for Enhanced Cloud Communication

Updated Category News Views 254

ConnX landed a hefty contract back in 2024 with the Southeastern Pennsylvania Transportation Authority (SEPTA) for a major overhaul of their communications network. The deal’s supposed to create a seamless communication experience, but you know how these things go—desks are skeptical about the actual impact. SEPTA's Communication Crisis: Is Cloud the Answer? SEPTA,...

Continue Reading
Kinepolis Group Announces Upcoming Dividend Payment Details

Updated Category News Views 197

Kinepolis Group Dividend Announcement The Kinepolis Group NV is pleased to inform its shareholders of an upcoming dividend payout, a noteworthy event for investors looking to maximize their returns. Dividend Payment Details The company has officially announced a gross dividend of €0.55 per share. After the deduction of the standard 30% withholding tax, shareholders will...

Continue Reading
Cargotec Board Restructures Ahead of Exciting Name Change

Updated Category News Views 229

Cargotec's Board of Directors Restructuring Meeting Highlights Cargotec Corporation has made significant decisions during its recent Board of Directors meeting, as it prepares for exciting changes ahead. Notably, the Board has elected Jukka Moisio as Chair, continuing a strong leadership footprint. Alongside him, Casimir Lindholm has been appointed Vice Chair, effective...

Continue Reading